{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"3.42","value":"2.71"},{"groupId":"OG001","lowerLimit":"0.03","upperLimit":"4.8","value":"1.91"},{"groupId":"OG002","lowerLimit":"0.03","upperLimit":"2.14","value":"0.89"},{"groupId":"OG003","lowerLimit":"0.03","upperLimit":"2.04","value":"1.33"},{"groupId":"OG004","lowerLimit":"0.03","upperLimit":"2.04","value":"2"},{"groupId":"OG005","lowerLimit":"0.03","upperLimit":"3.52","value":"0.53"},{"groupId":"OG006","lowerLimit":"0.03","upperLimit":"0.03","value":"0.03"},{"groupId":"OG007","lowerLimit":"0.03","upperLimit":"2.5","value":"0.03"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"17"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of start of treatment to the first date of the observed clinical or radiologically documented progressive disease or death due to any cause, whichever occurs first, was estimated and reported for all evaluable participants. For participants who were not known to have died or progressed as of the data-inclusion cut-off date, PFS time was censored at the date of the last objective progression-free disease assessment prior to the date of any subsequent systematic anticancer therapy.","dispersionType":"Full Range","groups":[{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG000","title":"Cohort A - 150mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG001","title":"Cohort A - 300mg QD LY3475070"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG002","title":"Cohort A - 300mg BID LY3475070"},{"description":"Participants received 600mg LY3475070 orally once daily on a 21-day cycle until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG003","title":"Cohort A - 600mg QD LY3475070"},{"description":"Participants received 150mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG004","title":"Cohort B - 150mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 150mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG005","title":"Cohort B - 150mg BID LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally once daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study discontinuation is met.","id":"OG006","title":"Cohort B - 300mg QD LY3475070 + Pembrolizumab"},{"description":"Participants received 300mg LY3475070 orally twice daily on a 21-day cycle in combination with an intravenous infusion of 200mg pembrolizumab on day 1 until progressive disease, unacceptable toxicity or other criterion for study","id":"OG007","title":"Cohort B - 300mg BID LY3475070 + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"All enrolled participants in phase1a who received at least one dose of LY3475070 (including censored). Number of participants censored: 150mg QD LY3475070=1, 300mg QD LY3475070=1, 300mg BID LY3475070=4, 600mg QD LY3475070=1, 150mg QD LY3475070 + pembrolizumab=2, 150mg BID LY3475070 + pembrolizumab=5, 300mg QD LY3475070 + pembrolizumab=1, 300mg BID LY3475070 + pembrolizumab=14.","reportingStatus":"POSTED","timeFrame":"Baseline to Objective Progression or Death Due to Any Cause (Estimated at up to 10.4 Months)","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}